• Sebastian T Tong, Zihan Zheng, Maria G Prado, Imara I West, Joseph W LeMaster, Mary A Hatch, Lili S Szabo, Tracy M Anastas, Kris Pui Kwan Ma, and Kari A Stephens.
• From the University of Washington, Seattle, WA (STT, ZZ, MGP, IIW, MAH, LSS, TMA, KPKM, KAS); University of Kansas Medical Center , Kansas City, KS (JWL).
• J Am Board Fam Med. 2024 Mar 1; 37 (2): 290294290-294.

BackgroundThe COVID-19 pandemic disrupted how primary care patients with chronic pain received care. Our study sought to understand how long-term opioid therapy (LtOT) for chronic pain changed over the course of the pandemic overall and for different demographic subgroups.MethodsWe used data from electronic health records of 64 primary care clinics across Washington state and Idaho to identify patients who had a chronic pain diagnosis and were receiving long-term opioid therapy. We defined 10-month periods in 2019 to 2021 as prepandemic, early pandemic and late pandemic and used generalized estimating equations analysis to compare across these time periods and demographic characteristics.ResultsWe found a proportional decrease in LtOT for chronic pain in the early months of the pandemic (OR = 0.94, P = .007) followed by an increase late pandemic (OR = 1.08, P = .002). Comparing late pandemic to prepandemic, identifying as Asian or Black, having fewer comorbidities, or living in an urban area were associated with higher likelihood of being prescribed LtOT.DiscussionThe use of LtOT for chronic pain in primary care has increased from before to after the COVID-19 pandemic with racial/ethnic and geographic disparities. Future research is needed to understand these disparities in LtOT and their effect on patient outcomes.© Copyright 2024 by the American Board of Family Medicine.

29 keywords...

hide…